Joint marker for diagnosing bladder cancer, kit and application
A kit and marker technology, applied in the field of bladder cancer kits and systems, can solve the problems of complex diagnosis of bladder cancer and low sensitivity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0067] 1. Serum Sample Collection
[0068] Before collection, all volunteers included in the study signed the informed consent.
[0069]96 cases of bladder cancer patients and 49 cases of normal control group were fasted overnight the day before, and blood was collected the next morning. The collected blood samples were left to stand for 30 minutes, centrifuged at 4500rpm / min at 4°C for 15 minutes, and the serum was collected and stored in a -80°C refrigerator for later use.
[0070] 2. Analysis method
[0071] 2.1 Serum sample pretreatment
[0072] The blood sample was thawed at 4°C, and 100 μL of serum sample was taken, and 400 μL of the extraction solution containing the internal standard (that is, containing the internal standard 1- 13 Methanol solution of C-valine, D4-chenodeoxycholic acid, D3-palmitic acid, see Table 2 for the concentration of internal standard) Precipitate protein; after shaking, centrifuge at 14000g, 4°C for 15 minutes; take 400μL of supernatant and...
Embodiment 2
[0085] Another batch of serum samples was collected to validate the combined markers of bladder cancer, including 32 patients with bladder cancer and 17 normal controls.
[0086] 1. Serum Sample Collection
[0087] The sample collection method is the same as in Example 1.
[0088] 2. Analysis method
[0089] 2.1 The serum sample pretreatment method is the same as that in Example 1.
[0090] 2.2 Ultra-high performance liquid chromatography mass spectrometry analysis
[0091] The liquid phase and mass spectrometry conditions are the same as in Example 1.
[0092] 2.3 Verification results.
[0093] The contents of choline alfoscerate, cystine, dodecenoic acid, eicosenoic acid, and chenodeoxycholic acid were significantly different in the bladder cancer patient group and the normal control group. Using the binary logistic regression equation, when the cut-off value of 0.500 is used for the combined markers, the results are shown in Table 4 below.
[0094] Table 4.
[0095] ...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com